Simon Lykkemark

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 5

Top Topics

Epidermal Growth Factor Receptor

Dendritic Cells

Small Cell Lung Cancer

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Laura Rubio-Pérez, Rodrigo Lázaro-Gorines, Seandean Lykke Harwood, Marta Compte, Rocío Navarro, Antonio Tapia-Galisteo, Jaume Bonet, Belén Blanco, Simon Lykkemark, Ángel Ramírez-Fernández, Mariola Ferreras-Gutierrez, Carmen Domínguez-Alonso, Laura Díez-Alonso, Alejandro Segura-Tudela, Oana Hangiu, Ainhoa Erce-Llamazares, Francisco J Blanco, Cruz Santos, José Luis Rodriguez-Peralto, Laura Sanz, Luis Alvarez-Vallina
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response. Oncoimmunology 12 (1) (2023)
Laura Rubio-Pérez, Rodrigo Lázaro-Gorines, Seandean Lykke Harwood, Marta Compte, Rocío Navarro, Antonio Tapia-Galisteo, Jaume Bonet, Belén Blanco, Simon Lykkemark, Ángel Ramírez-Fernández, Mariola Ferreras-Gutierrez, Carmen Domínguez-Alonso, Laura Díez-Alonso, Alejandro Segura-Tudela, Oana Hangiu, Ainhoa Erce-Llamazares, Francisco J Blanco, Cruz Santos, José Luis Rodriguez-Peralto, Laura Sanz, Luis Alvarez-Vallina
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response. Oncoimmunology 12 (1) (2023)
Laura Rubio-Pérez, Rodrigo Lázaro-Gorines, Seandean Lykke Harwood, Marta Compte, Rocío Navarro, Antonio Tapia-Galisteo, Jaume Bonet, Belén Blanco, Simon Lykkemark, Ángel Ramírez-Fernández, Mariola Ferreras-Gutierrez, Carmen Domínguez-Alonso, Laura Díez-Alonso, Alejandro Segura-Tudela, Oana Hangiu, Ainhoa Erce-Llamazares, Francisco J Blanco, Cruz Santos, José Luis Rodriguez-Peralto, Laura Sanz, Luis Alvarez-Vallina
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response. Oncoimmunology 12 (1) (2023)
Laura Rubio-Pérez, Rodrigo Lázaro-Gorines, Seandean Lykke Harwood, Marta Compte, Rocío Navarro, Antonio Tapia-Galisteo, Jaume Bonet, Belén Blanco, Simon Lykkemark, Ángel Ramírez-Fernández, Mariola Ferreras-Gutierrez, Carmen Domínguez-Alonso, Laura Díez-Alonso, Alejandro Segura-Tudela, Oana Hangiu, Ainhoa Erce-Llamazares, Francisco J Blanco, Cruz Santos, José Luis Rodriguez-Peralto, Laura Sanz, Luis Alvarez-Vallina
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response. Oncoimmunology 12 (1) (2023)
Laura Rubio-Pérez, Rodrigo Lázaro-Gorines, Seandean Lykke Harwood, Marta Compte, Rocío Navarro, Antonio Tapia-Galisteo, Jaume Bonet, Belén Blanco, Simon Lykkemark, Ángel Ramírez-Fernández, Mariola Ferreras-Gutierrez, Carmen Domínguez-Alonso, Laura Díez-Alonso, Alejandro Segura-Tudela, Oana Hangiu, Ainhoa Erce-Llamazares, Francisco J Blanco, Cruz Santos, José Luis Rodriguez-Peralto, Laura Sanz, Luis Alvarez-Vallina
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response. Oncoimmunology 12 (1) (2023)